EphA3 biology and cancer

Growth Factors

Volumn 32, Issue 6, 2014, Pages 176-189

  Janes, Peter W ^a   Slape, Christopher I ^a   Farnsworth, Rae H ^a   Atapattu, Lakmali ^a   Scott, Andrew M ^b   Vail, Mary E ^a  

^a MONASH UNIVERSITY   (Australia)

^b AUSTIN HOSPITAL   (Australia)

Author keywords

Cancer; Cell cell interaction; Eph receptor; Ephrin

Indexed keywords

EPHRIN RECEPTOR A3; KB 004; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER STEM CELL; CELL ADHESION; CELL DIFFERENTIATION; CELL FUNCTION; CELL INTERACTION; CONFORMATIONAL TRANSITION; CYTOSKELETON; ENZYME ACTIVITY; ENZYME REGULATION; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA STEM CELL; LIGAND BINDING; NEOPLASM; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SOLID TUMOR; SOMATIC MUTATION; TUMOR MICROENVIRONMENT;

EID: 84918782221     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2014.982276     Document Type: Article

References (175)

1. Adams RH, Eichmann A. 2010. Axon guidancemolecules in vascular patterning. Cold Spring Harb Perspect Biol 2:a001875
2. Adams RH, Wilkinson GA, Weiss C, Diella F, Gale NW, Deutsch U, Risau W, Klein R. 1999. Roles of ephrinB ligands and EphB receptors in cardiovascular development: Demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 13:295-306
3. Aoki M, Yamashita T, Tohyama M. 2004. EphA receptors direct the differentiation of mammalian neural precursor cells through a mitogen-Activated protein kinase-dependent pathway. J Biol Chem 279:32643-32650
4. Arruga F, Messa F, Carturan S, Pradatto M, Maff C, Pautasso M, Panuzzo C, et al. 2009. EphA3 is abnormally expressed in chronic myeloproliferative disorders and could represent a new molecular target. Proc Am Assoc Cancer Res AACR 2009:Abstract nr 2866
5. Ashton JM, Balys M, Neering SJ, Hassane DC, Cowley GR, David EM, Peter GE, et al. 2012. Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells. Cell Stem Cell 11:359-372
6. Atapattu L, Lackmann M, Janes PW. 2014. The role of proteases in regulating Eph/ephrin signalling. Cell Adh Migr, in press
7. Atapattu L, Saha N, Llerena C, Vail ME, Scott AM, Nikolov DB, Lackmann M, Janes PW. 2012. Antibodies Binding the ADAM10 Substrate Recognition Domain Inhibit Eph Function. J Cell Sci 125:6084-6093
8. Balakrishnan A, Bleeker FE, Lamba S, Rodolfo M, Daniotti M, Scarpa A, van Tilborg AA, et al. 2007. Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res 67:3545-3550
9. Bao B, Azmi AS, Ali S, Ahmad A, Li Y, Banerjee S, Kong D, Sarkar FH. 2012. The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta 1826:272-296
10. Barcellos-de-Souza P, Gori V, Bambi F, Chiarugi P. 2013. Tumor microenvironment: Bone marrow-mesenchymal stem cells as key players. Biochim Biophys Acta 1836:321-335
11. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, Markowitz S, et al. 2003. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300:949
12. Bea S, Valdes-Mas R, Navarro A, Salaverria I, Martin-Garcia D, Jares P, Gine E, et al. 2013. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A 110: 18250-18255
13. Bianco P, Robey PG, Simmons PJ. 2008. Mesenchymal stem cells: Revisiting history, concepts, and assays. Cell Stem Cell 2:313-319
14. Binda E, Visioli A, Giani F, Lamorte G, Copetti M, Pitter KL, Huse JT, et al. 2012. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell 22:765-780
15. Birgbauer E, Cowan CA, Sretavan DW, Henkemeyer M. 2000. Kinase independent function of EphB receptors in retinal axon pathfinding to the optic disc from dorsal but not ventral retina. Development 127: 1231-1241
16. Bonifaci N, Górski B, Masojć B, Wokolorczyk D, Jakubowska A, De?bniak T, Berenguer A, et al. 2010. Exploring the link between germline and somatic genetic alterations in breast carcinogenesis. PLoS ONE 5:e14078
17. Bosco MC, Pierobon D, Blengio F, Raggi F, Vanni C, Gattorno M, Eva A, et al. 2011. Hypoxia modulates the gene expression profile of immunoregulatory receptors in human mature dendritic cells: Identification of TREM-1 as a novel hypoxic marker in vitro and in vivo. Blood 117:2625-2639
18. Boyd AW, Bartlett PF, Lackmann M. 2014. Therapeutic targeting of EPH receptors and their ligands. Nat Rev Drug Discov 13:39-62
19. Boyd AW, Ward LD, Wicks IP, Simpson RJ, Salvaris E, Wilks A, Welch K, et al. 1992. Isolation and characterization of a novel receptor-Type protein tyrosine kinase (hek) from a human pre-B cell line. J Biol Chem 267: 3262-3267
20. Brantley-Sieders DM, Caughron J, Hicks D, Pozzi A, Ruiz JC, Chen J. 2004. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinasemediated Rac1 GTPase activation. J Cell Sci 117:2037-2049.
21. Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM, Coffman K, et al. 2008. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 118: 64-78
22. Brennaman LH, Moss ML, Maness PF. 2014. EphrinA/EphA-induced Ectodomain Shedding of Neural Cell Adhesion Molecule Regulates Growth Cone Repulsion Through ADAM10 Metalloprotease. J Neurochem 128:267-279
23. Brown A, Yates PA, Burrola P, Ortuno D, Vaidya A, Jessell TM, Pfaff SL, O'Leary DD, Lemke G. 2000. Topographic mapping from the retina to the midbrain is controlled by relative but not absolute levels of EphA receptor signaling. Cell 102:77-88
24. Bush JO, Soriano P. 2010. Ephrin-B1 forward signaling regulates craniofacial morphogenesis by controlling cell proliferation across Eph-ephrin boundaries. Genes Dev 24:2068-2080
25. Caivano A, La Rocca F, Laurenzana I, Favole A, Airoldi I, Di Carlo E, Gaidano V, et al. 2013. EphA3 as a molecular target in multiple myeloma: Opportunity for a novel therapeutic approach with a specific monoclonal antibody. Blood (ASH Annual Meeting Abstracts) 122:3211
26. Carter N, Nakamoto T, Hirai H, Hunter T. 2002. EphrinA1-induced cytoskeletal re-organization requires FAK and p130(cas). Nat Cell Biol 4:565-573
27. Casey J, Magalhaes T, Conroy J, Regan R, Shah N, Anney R, Shields D, et al. 2012. A novel approach of homozygous haplotype sharing identifies candidate genes in autism spectrum disorder. Hum Genet 131:565-579
28. Castellani CA, Awamleh Z, Melka MG, O'Reilly RL, Singh SM. 2014. Copy number variation Distribution in six monozygotic twin pairs discordant for schizophrenia. Twin Res Hum Genet 17: 108-120
29. Chang L-C, Jamain S, Lin C-W, Rujescu D, Tseng GC, Sibille E. 2014. A conserved BDNF, glutamate- And GABA-enriched gene module related to human Depression identified by coexpression meta-Analysis and DNA variant genome-wide association studies. PLoS ONE 9: e90980
30. Charmsaz S, Miller KJ, Day BW, El-Ajeh F, Yarranton GT, Bebbington CR, Scott AM, et al. 2013. EphA3 as a target for monoclonal antibody therapy for acute leukemia. Blood (ASH Annual Meeting Abstracts) 122:5013
31. Chen J, Guo L, Peiffer DA, Zhou L, Chan OTM, Bibikova M, Wickham-Garcia E, et al. 2008. Genomic profiling of 766 cancer-related genes in archived esophageal normal and carcinoma tissues. Int J Cancer 122:2249-2254
32. Chen J, Song W, Amato K. 2014. Eph receptor tyrosine kinases in cancer stem cells. Cytokine Growth Factor Rev (in press). doi: http:// dx.doi.org/10.1016/j.cytogfr.2014.05.001
33. Cheng HJ, Nakamoto M, Bergemann AD, Flanagan JG. 1995. Complementary gradients in expression and binding of ELF-1 and Mek4 in Development of the topographic retinotectal projection map. Cell 82:371-381
34. Chiappalupi S, Riuzzi F, Fulle S, Donato R, Sorci G. 2014. Defective RAGE activity in embryonal rhabdomyosarcoma cells results in high PAX7 levels that sustain migration and invasiveness. Carcinogenesis 35:2382-2392
35. Chiari R, Hames G, Stroobant V, Texier C, Maillere B, Boon T, Coulie PG. 2000. Identification of a tumor-specific shared antigen Derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res 60:4855-4863
36. Choi Y, Syeda F, Walker JR, Finerty Jr PJ, Cuerrier D, Wojciechowski A, Liu Q, et al. 2009. Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett 19: 4467-4470
37. Cilloni D, Arruga F, Carturan S, Messa F, Pradotto M, Defilippi I, Pautasso M, et al. 2008. EphA3 kinase is constitutively activated in chronic myeloid leukaemia during progression to accelerated and blast crisis and it could represent a new molecular target. ASH Annual Meeting Abstract, Paper 9247
38. Clifford N, Smith LM, Powell J, Gattenlohner S, Marx A, O'Connor R. 2008. The EphA3 receptor is expressed in a subset of rhabdomyosarcoma cell lines and suppresses cell adhesion and migration. J Cell Biochem 105:1250-1259
39. Connor RJ, Menzel P, Pasquale EB. 1998. Expression and tyrosine phosphorylation of Eph receptors suggest multiple mechanisms in patterning of the visual system. Dev Biol 193:21-35
40. Cooke JE, Kemp HA, Moens CB. 2005. EphA4 is required for cell adhesion and rhombomere-boundary formation in the zebrafish. Curr Biol 15:536-542
41. Corbo V, Ritelli R, Barbi S, Funel N, Campani D, Bardelli A, Scarpa A. 2010. Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in Ductal and ampulla of vater carcinomas. PLoS ONE 5:e12653
42. Cortina C, Palomo-Ponce S, Iglesias M, Fernandez-Masip JL, Vivancos A, Whissell G, Huma M, et al. 2007. EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nat Genet 39:1376-1383
43. Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G, Teague J, et al. 2005. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65:7591-7595
44. Davis S, Gale NW, Aldrich TH, Maisonpierre PC, Lhotak V, Pawson T, Goldfarb M, Yancopoulos GD. 1994. Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science 266:816-819
45. Davis TL, Walker JR, Loppnau P, Butler-Cole C, Allali-Hassani A, Dhe-Paganon S. 2008. Autoregulation by the juxtamembrane region of the human ephrin receptor tyrosine kinase A3 (EphA3). Structure 16: 873-884
46. Day B, To C, Himanen JP, Smith FM, Nikolov DB, Boyd AW, Lackmann M. 2005. Three distinct molecular surfaces in ephrin-A5 are essential for a functional interaction with EphA3. J Biol Chem 280: 26526-26532
47. Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, Jamieson PR, et al. 2013. EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. Cancer Cell 23: 238-248
48. Day BW, Stringer BW, Boyd AW 2014. Eph receptors as therapeutic targets in glioblastoma. Br J Cancer 111:1255-1261
49. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, et al. 2008. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069-1075
50. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, et al. 2012. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481:506-510
51. Dobrzanski P, Hunter K, Jones-Bolin S, Chang H, Robinson C, Pritchard S, Zhao H, Ruggeri B. 2004. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res 64: 910-919
52. Dottori M, Down M, Huttmann A, Fitzpatrick DR, Boyd AW. 1999. Cloning and characterization of EphA3 (Hek) gene promoter: DNA methylation regulates expression in hematopoietic tumor cells. Blood 94:2477-2486
53. Durbin L, Brennan C, Shiomi K, Cooke J, Barrios A, Shanmugalingam S, Guthrie B, et al. 1998. Eph signaling is required for segmentation and differentiation of the somites. Genes Dev 12: 3096-3109
54. Easty DJ, Bennett DC. 2000. Protein tyrosine kinases in malignant melanoma. Melanoma Res 10:401-411
55. Easty DJ, Herlyn M, Bennett DC. 1995. Abnormal protein tyrosine kinase gene expression During melanoma progression and metastasis. Int J Cancer 60:129-136
56. Elowe S, Holland SJ, Kulkarni S, Pawson T. 2001. Downregulation of the Ras-mitogen-Activated protein kinase pathway by the EphB2 receptor tyrosine kinase is required for ephrin-induced neurite retraction. Mol Cell Biol 21:7429-7441
57. Fawcett JP, Georgiou J, Ruston J, Bladt F, Sherman A, Warner N, Saab BJ, et al. 2007. Nck adaptor proteins control the organization of neuronal circuits important for walking. Proc Natl Acad Sci USA 104: 20973-20978
58. Finger C, Escher C, Schneider D. 2009. The single transmembrane domains of human receptor tyrosine kinases encode self-interactions. Sci Signal 2:ra56
59. Foo SS, Turner CJ, Adams S, Compagni A, Aubyn D, Kogata N, Lindblom P, et al. 2006. Ephrin-B2 controls cell motility and adhesion During blood-vessel-wall assembly. Cell 124:161-173
60. Fournier MV, Martin KJ, Kenny PA, Xhaja K, Bosch I, Yaswen P, Bissell MJ. 2006. Gene expression signature in organized and growth-Arrested mammary acini predicts good outcome in breast cancer. Cancer Res 66:7095-7102
61. Fox BP, Tabone CJ, Kandpal RP. 2006. Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines. Biochem Biophys Res Commun 342:1263-1272
62. Frieden LA, Townsend TA, Vaught DB, Delaughter DM, Hwang Y, Barnett JV, Chen J. 2010. Regulation of heart valve morphogenesis by Eph receptor ligand, ephrin-A1. Dev Dynam 239:3226-3234
63. Gallarda BW, Bonanomi D, Muller D, Brown A, Alaynick WA, Andrews SE, Lemke G, et al. 2008. Segregation of axial motor and sensory pathways via heterotypic trans-Axonal signaling. Science 320: 233-236
64. Gerety SS, Anderson DJ. 2002. Cardiovascular ephrinB2 function is essential for embryonic angiogenesis. Development 129:1397-1410
65. Gerety SS, Wang HU, Chen ZF, Anderson DJ. 1999. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 4: 403-414
66. Greene AC, Lord SJ, Tian A, Rhodes C, Kai H, Groves JT. 2014. Spatial organization of EphA2 at the cell-cell interface modulates transendocytosis of EphrinA1. Biophys J 106:2196-2205
67. Guan M, Liu L, Zhao X, Wu Q, Yu B, Shao Y, Yang H, et al. 2011. Copy number variations of EphA3 are associated with multiple types of hematologic malignancies. Clin Lymphoma Myeloma Leuk 11:50-53
68. Harrison JS, Rameshwar P, Chang V, Bandari P. 2002. Oxygen saturation in the bone marrow of healthy volunteers. Blood 99:394
69. Hattori M, Osterfield M, Flanagan JG. 2000. Regulated cleavage of a contact-mediated axon repellent. Science 289:1360-1365
70. Herath NI, Spanevello MD, Doecke JD, Smith FM, Pouponnot C, Boyd AW. 2012. Complex Expression Patterns of Eph Receptor Tyrosine Kinases and Their Ephrin Ligands in Colorectal Carcinogenesis. Eur J Cancer 48:753-762
71. Hess AR, Margaryan NV, Seftor EA, Hendrix MJ. 2007. Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vasculogenesis: Role of the Eph receptors. Dev Dynam 236:3283-3296
72. Himanen JP, Chumley MJ, Lackmann M, Li C, Barton WA, Jeffrey PD, Vearing C, et al. 2004. Repelling class discrimination: Ephrin-A5 binds to and activates EphB2 receptor signaling. Nat Neurosci 7: 501-509
73. Himanen JP, Rajashankar KR, Lackmann M, Cowan CA, Henkemeyer M, Nikolov DB. 2001. Crystal structure of an Eph receptor-ephrin complex. Nature 414:933-938
74. Himanen JP, Yermekbayeva L, Janes PW, Walker JR, Xu K, Atapattu L, Rajashankar KR, et al. 2010. Architecture of Eph receptor clusters. Proc Natl Acad Sci USA 107:10860-10865
75. Hinoue T, Weisenberger DJ, Pan F, Campan M, Kim M, Young J, Whitehall VL, et al. 2009. Analysis of the association between CIMP and BRAFV600E in colorectal cancer by DNA Methylation Profiling. PLoS ONE 4:e8357
76. Holland SJ, Gale NW, Gish GD, Roth RA, Songyang Z, Cantley LC, Henkemeyer M, et al. 1997. Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells. EMBO J 16:3877-3888
77. Holmberg J, Clarke DL, Frisen J. 2000. Regulation of repulsion versus adhesion by different splice forms of an Eph receptor. Nature 408: 203-206
78. Hou F, Yuan W, Huang J, Qian L, Chen Z, Ge J, Wu S, et al. 2012. Overexpression of EphA2 correlates with epithelial-mesenchymal transition-related proteins in gastric cancer and their prognostic importance for postoperative patients. Medl Oncol 29:2691-2700
79. Hu T, Shi G, Larose L, Rivera GM, Mayer BJ, Zhou R. 2009. Regulation of process retraction and cell migration by EphA3 is mediated by the adaptor protein Nck1. Biochemistry 48:6369-6378
80. Huang J, Xiao D, Li G, Ma J, Chen P, Yuan W, Hou F, et al. 2014. EphA2 promotes epithelial-mesenchymal transition through the Wnt/ [beta]-catenin pathway in gastric cancer cells. Oncogene 33: 2737-2747
81. Huang X, Wu D, Jin H, Stupack D, Wang JY. 2008. Induction of cell retraction by the combined actions of Abl-CrkII and Rho-ROCK1 signaling. J Cell Biol 183:711-723
82. Iacobucci I, Ottaviani E, Guadagnuolo V, Paolini S, Cilloni D, Messa F, Candoni A, et al. 2010. High-resolution molecular allelokaryotyping identifies novel genomic alterations in acute promyelocytic leukemia (APL). Proc Am Assoc Cancer Res 70:Abstract nr 656
83. Iwamasa H, Ohta K, Yamada T, Ushijima K, Terasaki H, Tanaka H. 1999. Expression of Eph receptor tyrosine kinases and their ligands in chick embryonic motor neurons and hindlimb muscles. Dev Growth Differ 41:685-698
84. Janes PW, Adikari S, Lackmann M. 2008. Eph/Ephrin signalling and function in oncogenesis: Lessons from embryonic development. Curr Cancer Drug Targets 8:473-479
85. Janes PW, Griesshaber B, Atapattu L, Nievergall E, Hii LL, Mensinga A, Chheang C, et al 2011. Eph receptor function is modulated by heterooligomerization of A and B type Eph receptors. J Cell Biol 195: 1033-1045
86. Janes PW, Saha N, Barton WA, Kolev MV, Wimmer-Kleikamp SH, Nievergall E, Blobel CP, et al. 2005. Adam meets Eph: An ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 123:291-304
87. Janes PW, Wimmer-Kleikamp SH, Frangakis AS, Treble K, Griesshaber B, Sabet O, Grabenbauer M, et al. 2009. Cytoplasmic relaxation of active Eph controls ephrin shedding by ADAM10. PLoS Biol 7: e1000215
88. Jorgensen C, Sherman A, Chen GI, Pasculescu A, Poliakov A, Hsiung M, Larsen B, et al. 2009. Cell-specific information processing in segregating populations of eph receptor ephrin-expressing cells. Science 326:1502-1509
89. Julien SG, Dubé, N., Hardy S, Tremblay ML. 2011. Inside the human cancer tyrosine phosphatome. Nat Rev Cancer 11:35-49
90. Kahn J, Walcheck B, Migaki GI, Jutila MA, Kishimoto TK. 1998. Calmodulin regulates L-selectin adhesion molecule expression and function through a protease-dependent mechanism. Cell 92:809-818
91. Kalluri R, Zeisberg M. 2006. Fibroblasts in cancer. Nat Rev Cancer 6: 392-401
92. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, et al. 2010. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466:7308
93. Kawakami Y, Uchiyama Y, Rodriguez Esteban C, Inenaga T, Koyano-Nakagawa N, Kawakami H, Marti M, et al. 2009. Sall genes regulate region-specific morphogenesis in the mouse limb by modulating Hox activities. Development 136:585-594
94. Keane N, Freeman C, Swords R, Giles FJ. 2012. EPHA3 as a novel therapeutic target in the hematological malignancies. Expert Rev Hematol 5:325-340
95. Kilpatrick TJ, Brown A, Lai C, Gassmann M, Goulding M, Lemke G. 1996. Expression of the Tyro4/Mek4/Cek4 gene specifically marks a subset of embryonic motor neurons and their muscle targets. Mol Cell Neurosci 7:62-74
96. Kilpinen S, Autio R, Ojala K, Iljin K, Bucher E, Sara H, Pisto T, et al. 2008. Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues. Genome Biol 9:R139
97. Kullander K, Mather NK, Diella F, Dottori M, Boyd AW, Klein R. 2001. Kinase-dependent and kinase-independent functions of EphA4 receptors in major axon tract formation in vivo. Neuron 29:73-84
98. Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, Scehnet J, et al. 2006. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol 169:279-293
99. Lackmann M, Bucci T, Mann RJ, Kravets LA, Viney E, Smith F, Moritz RL, et al. 1996. Purification of a ligand for the EPH-like receptor HEK using a biosensor-based affinity detection approach. Proc Natl Acad Sci USA 93:2523-2527
100. Lackmann M, Mann RJ, Kravets L, Smith FM, Bucci TA, Maxwell KF, Howlett GJ, et al. 1997. Ligand for EPH-related kinase (LERK) 7 is the preferred high affinity ligand for the HEK receptor. J Biol Chem 272:16521-16530
101. Lackmann M, Oates AC, Dottori M, Smith FM, Do C, Power M, Kravets L, Boyd AW. 1998. Distinct subdomains of the EphA3 receptor mediate ligand binding and receptor dimerization. J Biol Chem 273:20228-20237
102. Lawrenson ID, Wimmer-Kleikamp SH, Lock P, Schoenwaelder SM, Down M, Boyd AW, Alewood PF, Lackmann M. 2002. Ephrin-A5 induces rounding, blebbing and de-Adhesion of EphA3- expressing 293T and melanoma cells by CrkII and Rho-mediated signalling. J Cell Sci 115:1059-1072
103. Leone M, Cellitti J, Pellecchia M. 2008. NMR studies of a heterotypic Sam-Sam domain association: The interaction between the lipid phosphatase Ship2 and the EphA2 receptor. Biochemistry 47: 12721-12728
104. Li W, Fan J, Woodley DT. 2001. Nck/Dock: An adapter between cell surface receptors and the actin cytoskeleton. Oncogene 20:6403-6417
105. Lin CS, Lue TF. 2013. Defining vascular stem cells. Stem Cells Dev 22: 1018-1026
106. Lisabeth EM, Fernandez C, Pasquale EB. 2012. Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms. Biochemistry 51:1464-1475
107. Lu C, Yang Z, Zhou L, Huang Z, Zhang H, Li J, Tao K, Xie B. 2013. High levels of EphA3 expression are associated with high invasive capacity and poor overall survival in hepatocellular carcinoma. Oncol Reports 30:2179-2186
108. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, et al. 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704-715
109. Marie-Egyptienne DT, Lohse I, Hill RP. 2013. Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. Cancer Lett 341:63-72
110. Martin-Rendon E, Hale SJ, Ryan D, Baban D, Forde SP, Roubelakis M, Sweeney D, et al. 2007. Transcriptional profiling of human cord blood CD133+ and cultured bone marrow mesenchymal stem cells in response to hypoxia. Stem Cells 25:1003-1012
111. Medici D, Shore EM, Lounev VY, Kaplan FS, Kalluri R, Olsen BR. 2010. Conversion of vascular endothelial cells into multipotent stemlike cells. Nat Med 16:1400-1406
112. Mosch B, Pietzsch D, Pietzsch J. 2012. Irradiation affects cellular properties and Eph receptor expression in human melanoma cells. Cell Adh Migr 6:113-125
113. Nievergall E, Janes PW, Stegmayer C, Vail ME, Haj FG, Teng SW, Neel BG, et al. 2010. PTP1B Regulates Eph Receptor Function and Trafficking. J Cell Biol 191:1189-1203
114. Nievergall E, Lackmann M, Janes PW. 2012. Eph-dependent cell-cell adhesion and segregation in Development and cancer. Cell Mol Life Sci 69:1813-1842
115. Noren NK, Foos G, Hauser CA, Pasquale EB. 2006. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol 8:815-825
116. Noren NK, Lu M, Freeman AL, Koolpe M, Pasquale EB. 2004. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci USA 101: 5583-5588
117. Oates AC, Lackmann M, Power MA, Brennan C, Down LM, Do C, Evans B, et al. 1999. An early developmental role for eph-ephrin interaction During vertebrate gastrulation. Mech Dev 83:77-94
118. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB. 2000. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19: 6043-6052
119. Palath V, Vekhande R, Lee A, Williams J, Zhang L, List AF, Boyd A, et al. 2009. A recombinant human antibody to EphA3 with proapoptotic and and enhanced ADCC activity shows selective cytotoxicity against myeloid leukemia cells and CD123-positive leukemic stem cells. Blood (ASH Annual Meeting Abstracts) 114:1728
120. Park IH, Kim KH, Choi HK, Shim JS, Whang SY, Hahn SJ, Kwon OJ, Oh IH. 2013. Constitutive stabilization of hypoxia-inducible factor alpha selectively promotes the self-renewal of mesenchymal progenitors and maintains mesenchymal stromal cells in an undifferentiated state. Exp Mol Med 45:e44
121. Pasquale EB. 2008. Eph-ephrin bidirectional signaling in physiology and disease. Cell 133:38-52
122. Pasquale EB. 2010. Eph receptors and ephrins in cancer: Bidirectional signalling and beyond. Nat Rev Cancer 10:165-180
123. Poliakov A, Cotrina ML, Pasini A, Wilkinson DG. 2008. Regulation of EphB2 activation and cell repulsion by feedback control of the MAPK pathway. J Cell Biol 183:933-947
124. Polyak K, Weinberg RA. 2009. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer 9:265-273
125. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N, Escaramis G, et al. 2011. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475: 101-105
126. Qin H, Noberini R, Huan X, Shi J, Pasquale EB, Song J. 2009. Structural characterization of the EphA4-Ephrin-B2 complex reveals new features enabling Eph-ephrin binding promiscuity. J Biol Chem 285: 644-654
127. Reber M, Burrola P, Lemke G. 2004. A relative signalling model for the formation of a topographic neural map. Nature 431:847-853
128. Reiss K, Saftig P. 2009. The ''A Disintegrin And Metalloprotease'' (ADAM) family of sheddases: Physiological and cellular functions. Semin Cell Dev Biol 20:126-137
129. Ross JS, Wang K, Elkadi OR, Tarasen A, Foulke L, Sheehan CE, Otto GA, et al. 2014. Next-generation Sequencing Reveals Frequent Consistent Genomic Alterations in Small Cell Undifferentiated Lung Cancer. J Clin Pathol 67:772-776
130. Ruiz JC, Robertson EJ. 1994. The expression of the receptor-protein tyrosine kinase gene, eck, is highly restricted during early mouse development. Mech Dev 46:87-100
131. Salaita K, Nair PM, Petit RS, Neve RM, Das D, Gray JW, Groves JT. 2010. Restriction of receptor movement alters cellular response: Physical force sensing by EphA2. Science 327:1380-1385
132. Seiradake E, Harlos K, Sutton G, Aricescu AR, Jones EY. 2010. An extracellular steric seeding mechanism for Eph-ephrin signaling platform assembly. Nat Struct Mol Biol 17:398-402
133. Shintani T, Ihara M, Sakuta H, Takahashi H, Watakabe I, Noda M. 2006. Eph receptors are negatively controlled by protein tyrosine phosphatase receptor type O. Nat Neurosci 9:761-769
134. Singh AP, Bafna S, Chaudhary K, Venkatraman G, Smith L, Eudy JD, Johansson SL, et al. 2008. Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgendependent and androgen-independent prostate cancer cells. Cancer Lett 259:28-38
135. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, et al. 2006. The consensus coding sequences of human breast and colorectal cancers. Science 314:268-274
136. Smith FM, Vearing C, Lackmann M, Treutlein H, Himanen J, Chen K, Saul A, et al. 2004a. Dissecting the EphA3/Ephrin-A5 interactions using a novel functional mutagenesis screen. J Biol Chem 279: 9522-9531
137. Smith LM, Walsh PT, Rudiger T, Cotter TG, McCarthy TV, Marx A, O'Connor R. 2004b. EphA3 is induced by CD28 and IGF-1 and regulates cell adhesion. Exp Cell Res 292:295-303
138. Solanas G, Cortina C, Sevillano M, Batlle E. 2011. Cleavage of Ecadherin by ADAM10 mediates epithelial cell sorting downstream of EphB signalling. Nat Cell Biol 13:1100-1107
139. Soverini S, Colarossi S, Gnani A, Castagnetti F, Astolfi A, Formica S, Palandri F, et al. 2009. High-resolution molecular allelokaryotyping of chronic myeloid leukemia patients in blast crisis by 6.0 SNP-Arrays shows a high frequency of uniparental disomy and focal copy number alterations affecting the whole sequence or specific exons of oncogenes and tumor suppressor genes. Blood (ASH Annual Meeting Abstracts) 114:2176
140. Stapleton D, Balan I, Pawson T, Sicheri F. 1999. The crystal structure of an Eph receptor SAM domain reveals a mechanism for modular dimerization. Nat Struct Biol 6:44-49
141. Stein E, Huynh-Do U, Lane AA, Cerretti DP, Daniel TO. 1998a. Nck recruitment to Eph receptor, EphB1/ELK, couples ligand activation to c-Jun kinase. J Biol Chem 273:1303-1308
142. Stein E, Lane AA, Cerretti DP, Schoecklmann HO, Schroff AD, Van Etten RL, Daniel TO. 1998b. Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev 12: 667-678
143. Stephen LJ, Fawkes AL, Verhoeve A, Lemke G, Brown A. 2007. A critical role for the EphA3 receptor tyrosine kinase in heart development. Dev Biol 302:66-79
144. Stubbs J, Palmer A, Vidovic M, Marotte LR. 2000. Graded expression of EphA3 in the retina and ephrin-A2 in the superior colliculus during initial development of coarse topography in the wallaby retinocollicular projection. Eur J Neurosci 12:3626-3636
145. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. 2000. The expression and distribution of the hypoxiainducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-Associated macrophages. Am J Pathol 157:411-421
146. Ting MJ, Day BW, Spanevello MD, Boyd AW. 2010. Activation of ephrin A proteins influences hematopoietic stem cell adhesion and trafficking patterns. Exp Hematol 38:1087-1098
147. To C, Farnsworth R, Vail M, Chheang C, Gargett C, Murone C, Llerena C, et al. 2014. Hypoxia-controlled EphA3 marks a human endometrium derived multipotent mesenchymal stromal cell that supports vascular growth. PLoS One (in press
148. Tognolini M, Hassan-Mohamed I, Giorgio C, Zanotti I, Lodola A. 2014. Therapeutic perspectives of Eph-ephrin system modulation. Drug Discov Today 19:661-669
149. Tsai CC, Chen YJ, Yew TL, Chen LL, Wang JY, Chiu CH, Hung SC. 2011. Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST. Blood 117:459-469
150. Tsai CC, Su PF, Huang YF, Yew TL, Hung SC. 2012. Oct4 and Nanog directly regulate Dnmt1 to maintain self-renewal and undifferentiated state in mesenchymal stem cells. Mol Cell 47:169-182
151. Vail ME, Murone C, Tan A, Hii L, Abebe D, Janes PW, Lee F-T, et al. 2014. Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment. Cancer Res 74:4470-4481
152. Valsesia A, Rimoldi D, Martinet D, Ibberson M, Benaglio P, Quadroni M, Waridel P, et al. 2011. Network-guided analysis of genes with altered somatic copy number and gene expression reveals pathways commonly perturbed in metastatic melanoma. PLoS ONE 6: e18369
153. Vearing C, Lee FT, Wimmer-Kleikamp S, Spirkoska V, To C, Stylianou C, Spanevello M, et al. 2005. Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: Potential as EphA3-specific tumor-Targeting reagents. Cancer Res 65:6745-6754
154. Vecchi M, Confalonieri S, Nuciforo P, Vigano MA, Capra M, Bianchi M, Nicosia D, et al. 2008. Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene 27:2148-2158
155. Vindis C, Teli T, Cerretti DP, Turner CE, Huynh-Do U. 2004. EphB1-mediated cell migration requires the phosphorylation of paxillin at Tyr-31/Tyr-118. J Biol Chem 279:27965-27970
156. Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC, Fenwick K, et al. 2012. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood 120:1077-1086
157. Wang HU, Chen ZF, Anderson DJ. 1998. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93:741-753
158. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, Wartman LD, et al. 2012. The origin and evolution of mutations in acute myeloid leukemia. Cell 150:264-278
159. Wiesner S, Wybenga-Groot LE, Warner N, Lin H, Pawson T, Forman-Kay JD, Sicheri F. 2006. A change in conformational dynamics underlies the activation of Eph receptor tyrosine kinases. Embo J 25: 4686-4696
160. Wimmer-Kleikamp SH, Janes PW, Squire A, Bastiaens PI, Lackmann M. 2004. Recruitment of Eph receptors into signaling clusters does not require ephrin contact. J Cell Biol 164:661-666
161. Wimmer-Kleikamp SH, Nievergall E, Gegenbauer K, Adikari S, Mansour M, Yeadon T, Boyd AW, et al. 2008. Elevated protein tyrosine phosphatase activity provokes Eph/ephrin-facilitated adhesion of pre-B leukemia cells. Blood 112:721-732
162. Wood LD, Calhoun ES, Silliman N, Ptak J, Szabo S, Powell SM, Riggins GJ, et al. 2006. Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers. Human Mutat 27:1060-1061
163. Wu Q, Suo Z, Risberg B, Karlsson MG, Villman K, Nesland JM. 2004. Expression of Ephb2 and Ephb4 in breast carcinoma. Pathol Oncol Res 10:26-33
164. Wybenga-Groot LE, Baskin B, Ong SH, Tong J, Pawson T, Sicheri F. 2001. Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 106:745-757
165. Xi H-Q, Wu X-S, Wei B, Chen L 2012. Aberrant expression of EphA3 in gastric carcinoma: Correlation with tumor angiogenesis and survival. J Gastroenterol 47:785-794
166. Xi H-Q, Zhao P 2011. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma. J Clin Pathol 64:498-503
167. Xu K, Tzvetkova-Robev D, Xu Y, Goldgur Y, Chan YP, Himanen JP, Nikolov DB. 2013. Insights into Eph receptor tyrosine kinase activation from crystal structures of the EphA4 ectodomain and its complex with ephrin-A5. Proc Natl Acad Sci USA 110:14634-14639
168. Yuan W, Chen Z, Wu S, Ge J, Chang S, Wang X, Chen J. 2009. Expression of EphA2 and E-cadherin in gastric cancer: Correlated with tumor progression and lymphogenous metastasis. Pathol Oncol Res 15:473-478
169. Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. 2007. Discovery of endothelial to mesenchymal transition as a source for carcinomaassociated fibroblasts. Cancer Res 67:10123-10128
170. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. 2001. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61:2301-2306
171. Zhao H, Huang D, Caflisch A. 2012. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics. Chem Med Chem 7:1983-1990
172. Zhong TP, Childs S, Leu JP, Fishman MC. 2001. Gridlock signalling pathway fashions the first embryonic artery. Nature 414:216-220
173. Zhuang G, Hunter S, Hwang Y, Chen J. 2007. Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-kinase-dependent Rac1 activation. J Biol Chem 282:2683-2694
174. Zhuang G, Song W, Amato K, Hwang Y, Lee K, Boothby M, Ye F, et al 2012. Effects of cancer-Associated EPHA3 mutations on lung cancer. J Natl Cancer Inst 104:1183-1198
175. Ziebarth JD, Bhattacharya A, Cui Y. 2012. Integrative analysis of somatic mutations altering microRNA targeting in cancer genomes. PLoS ONE 7:e47137